Outcomes of super-mini percutaneous nephrolithomy (SMP) and retrograde intrarenal surgery (RIRS) in the management of moderate size kidney stones
Abdul Aziz Nikzad 1, Huiwu Xing 1, Jun Wang 1, Mirwais Alizada 2, Zhankui Jia 1, Chaohui Gu 1, Dayong Jin 3, Jinjian Yang 1*
1 Department of Urology, The First Affiliated Hospital of Zhengzhou University, Jianshe Road, Erqi District, Zhengzhou City, 450052, Henan Province, People's Republic China
2 Department of Orthopedic, The Frist Affiliated Hospital of Zhengzhou University, Jianshe Road, Erqi District, Zhengzhou City, 450052, Henan Province, People’s Republic of China
3 Department of Urology, Central Hospital of Liaoyuan city, 586 Dongjida Road, Langshan district, Liaoyang city, Jilin Province, People's Republic of China
To evaluate and analyze the efficacy and safety of super-mini percutaneous nephrolithotomy (SMP) and retrograde intrarenal surgery (RIRS) in the management of moderate size renal calculi, we retrospectively collected and compared the date of 200 patients, who received either super-mini PCNL (n=100) or intrarenal retrograde surgery (n=100) at First Affiliated Hospital of Zhengzhou University between January 2016 and January 2019. The mean stone size was 17.86 ± 1.52 mm in the SMP group and 15.21 ± 1.68 mm in the RIRS group. The final stone-free rate (SFR) was significant in the SMP group as compared to RIRS group (97% vs 85% in the SMP and RIRS groups, p= 0.003). The operation time was comparable in both groups. The duration of hospitalization was 3.510 ± 1.480 days in the SMP group and 3.150 ± 1.044 days in the RIRS group (p = 0.048). The auxiliary rate was lower in SMP in contrast to RIRS group (10% vs 25%, p=0.005). Neither of the two procedures required blood transfusions. Complications between the SMP group and the RIRS group were not significantly different. We found out that SMP is more successful than RIRS with comparable complication rates, higher choice of treatment SFR and a lower auxiliary rate. Thus, SMP can be considered as a substitute for RIRS in the management of moderate size kidney stones.